Five Abstracts Accepted at ESMO, SITC, and CICON 2025

Accession Therapeutics is pleased to announce that five abstracts showcasing the company’s TROCEPT cancer immunotherapy platform have been accepted for presentation at three leading international oncology conferences in 2025.

The accepted abstracts span both preclinical and clinical research, highlighting the platform’s translational depth and breadth of potential application.

Abstract acceptances:

• International Cancer Immunotherapy Conference (CICON) 2025

  10-12 September, Utrecht, The Netherlands

  • One abstract on TROCEPT preclinical data

• European Society for Medical Oncology (ESMO) Congress 2025

  17-21 October, Berlin, Germany

  • One abstract from the TROCEPT-01 (ATTR-01) Phase 1 ATTEST study in patients with solid tumours

• Society for Immunotherapy of Cancer (SITC)’s 40^th 

  Anniversary Annual Meeting5–9 November, Maryland, USA

  • Two abstracts TROCEPT preclinical research

  • One abstract from the TROCEPT-01 (ATTR-01) Phase 1 ATTEST study in patients with solid tumours

“Our accepted abstracts at these prestigious meetings underscore the momentum of the TROCEPT platform and our focus on addressing tumours that remain invisible to the immune system,” said Bent Jakobsen, CEO. “By sharing both preclinical and clinical progress, we are able to demonstrate the translational strength of our approach to a global oncology audience.”

Further information will be available via the respective conference websites upon publication.